
DBVT Stock Forecast & Price Target
DBVT Analyst Ratings
Bulls say
DBV Technologies is a clinical-stage specialty biopharmaceutical company with a promising technology platform and lead product candidate, Viaskin Peanut, targeting pediatric peanut allergies. The company's cash position is expected to fund operations until at least 2Q27, providing significant runway for its upcoming regulatory submissions and potential launch. While there are clinical and financial risks involved, the company has clear potential for success in a large market, making it an attractive investment opportunity.
Bears say
DBV Technologies is facing potential delays in BLA submissions for both children and toddlers which could impact future revenue. In addition, adverse findings in the COMFORT-Toddler study, along with other potential R&D, regulatory, or commercial setbacks and new competitors in the immunotherapy space, could also hinder the company's growth and profitability. These factors contribute to a negative outlook on DBV Technologies stock as investors may have concerns about the company's ability to successfully bring its products to market and compete in a rapidly growing and competitive industry.
This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares